Table S2.
Clinicopathological parameters of 85 breast cancer serum samples analyzed for SLC50A1 protein level
| Parameters | Category | na | % |
|---|---|---|---|
| Age, years | Median 57.9 (range 29–81) | ||
| ≤57.9 | 38 | 44.7 | |
| >57.9 | 47 | 55.3 | |
| Histological gradeb | |||
| G1–2 | 46 | 54.1 | |
| G3 | 39 | 45.9 | |
| Lymph node statusc | |||
| pN0 | 45 | 52.9 | |
| pN1–3 | 40 | 47.1 | |
| Distant metastasisc | |||
| pM0 | 67 | 78.8 | |
| pM1 | 18 | 21.2 | |
| TNM stagec | |||
| I–II | 52 | 61.2 | |
| III–IV | 33 | 38.8 | |
| Estrogen receptor status | |||
| Negative (IRSd 0–2) | 39 | 45.9 | |
| Positive (IRSd 3–12) | 46 | 54.1 | |
| Progesterone receptor status | |||
| Negative (IRSd 0–2) | 41 | 48.2 | |
| Positive (IRSd 3–12) | 44 | 51.8 | |
| HER2 statuse | |||
| Negative | 56 | 65.9 | |
| Positive | 29 | 34.1 |
Notes:
a
Female patients with primary, unilateral breast cancer were included.
b
According to Bloom and Richardson and modified by Elston and Ellis.1
c
According to UICC TNM classification in breast cancer.2
d
IRS according to Remmele and Stegner.3
e
Overexpression of the ERBB2 gene (Her-2/neu) was diagnosed to the threshold of the DAKO score system based on the IHC assay. Uncertain cases were additionally validated by the FISH assay.
Abbreviations: FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; IRS, immunoreactive score.